| Home | |
| About CaptureSelect | |
| Products | |
| Custom Ligands | |
| News | |
| Literature | |
| Contact us | |
| Online ordering module | |
|
BAC B.V. Huizerstraatweg 28 1411 GP Naarden The Netherlands E: info@captureselect.com I: www.bac.nl |
Accelerating Biopharmaceutical Development
SBE's First Conference on Accelerating Biopharmaceutical Development
As the underlying technology for making antibodies, therapeutic proteins, and vaccines matures, speed and efficiency become more important. This conference will focus on recent developments (particularly new, "disruptive" technologies) that will be key to accelerating the pace and productivity of biopharmaceutical development. At this conference BAC will be present a poster on CaptureSelect® Ligands: Accelerating Biotherapeutic Purification Development.
CaptureSelect Ligands – Accelerating Biopharmaceutical Purification Development
An important factor in biotherapeutic development is the development of downstream purification processes that are capable of purifying bench, pilot, and commercial scale quantities of drug. In many cases downstream process development is done after the lead molecule has been developed, creating time, cost, purity and yield issues that affect the speed to clinic.
BAC provides custom affinity ligand discovery, development and manufacturing programs that can be initiated at any time during biotherapeutic product development. This creates unique biotherapeutic-specific processes that improve purity, yield, and speed to market while simultaneously providing PAT reagents to consistently assay product under varying cell culture and process conditions.